ATX-GD-59 (1.6mg)
$82.50
- Lyophilized peptides should be reconstituted using proper aseptic laboratory technique.
- Reconstitution must be performed using Canlab-supplied Bacteriostatic Water and handled in accordance with generally accepted research practices.
- Warranty related to reconstitution, sterility or material integrity applies only when Canlab Bacteriostatic Water is used.
- Use of third-party diluents or deviation from the provided handling guidance voids any applicable warranty.
For full handling instructions and limitations, see the Peptide Reconstitution section in our Product Warranty Policy Page →
Description
Introducing ATX-GD-59, a cutting-edge peptide-based therapy meticulously crafted for the management of Graves’ disease. With a molecular weight of 2529.26 and a molecular formula of C114H198N32O32, ATX-GD-59 surpasses research-grade benchmarks, highlighting our unwavering dedication to excellence and pioneering advancements.
ATX-GD-59 redefines medical paradigms through its innovative mode of action, engineered to emulate epitopes and effectively immobilize the leukocytes responsible for assaulting the thyroid. It obstructs the generation of anti-thyroid stimulating hormone receptor (TSHR) stimulatory antibodies, revolutionizing the approach beyond conventional treatments. This advanced strategy homes in on the immunological foundation of Graves’ disease, marking a transformative path in disease management brought forth by ATX-GD-59.
Additional Information
Benefits
Please review the complete product description and available supporting documentation for product-specific research information.
Mechanism of Action
Refer to the product description, certificate of analysis and applicable published research for product-specific information. No medical or therapeutic claims are made.
